Lupin gains over 2% on USFDA nod for Irbesartan

Pharma major Lupin gained on Wednesday after its subsidiary Lupin Pharmaceutical has received final approval for its Irbesartan tablets, 75 mg, 150 mg and 300 mg from the United States Food and Drugs Administration (FDA).This is to market a generic version of Sanofi Aventis US, LLC"s Avapro tablets, 75 mg, 150 mg and 300 mg strengths. Shares ofthe companyare trading at Rs 566.90, up Rs 12.1, or 2.18% at the Bombay Stock Exchange (BSE) on Wednesday at 1:08 p.m.The scrip has touched an intra-day high of Rs 568 and low of Rs 555.10. The total volume of shares traded at the BSE is 44,541.In the earlier session, the shares lost 1.35%, or Rs 7.6, at Rs 554.80. Currently, the stock is trading down 10.29% from its 52-week high of Rs 631.90 and above 38.44% over the 52-week low of Rs 409.50.

Share Price Movement Period Pricein Rs Gain/(Loss) in Rs in % 1 Week 567.40 (12.60) (2.22) 1 Month 572.95 (18.15) (3.17) 3 Months 571.60 (16.80) (2.94) 6 Months 549.55 5.25 0.96 1 Year 467.60 87.20 18.65 Note: Based on previous day closing price.